We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+4.25%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.01B
AUM Growth
+$52.2M
Cap. Flow
+$30.7M
Cap. Flow %
3.04%
Top 10 Hldgs %
32.72%
Holding
140
New
6
Increased
28
Reduced
47
Closed
15

Top Buys

Rank Stock Value
1
TDOC icon
Teladoc Health
TDOC
+$17.7M
2
HUM icon
Humana
HUM
+$13.6M
3
KTWO
K2M Group Holdings, Inc
KTWO
+$13.2M
4
FIT
Fitbit, Inc. Class A common stock
FIT
+$12.2M
5
ESPR
Esperion Therapeutics
ESPR
+$12.1M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$20.4M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$11.6M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$11.4M
4
THC icon
Tenet Healthcare
THC
+$9.34M
5
ONC
BeOne Medicines Ltd
ONC
+$8.53M

Sector Composition

Rank Sector Weight
1 Healthcare 95.24%
2 Industrials 0.39%
3 Financials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRC
26
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$13.7M 1.36%
157,919
-12,020
-7% -$1.03M
SUPN icon
27
Supernus Pharmaceuticals
SUPN
$2.79B
$13.2M 1.31%
288,800
+48,400
+20% +$2.02M
CNC icon
28
Centene
CNC
$32.8B
$12.8M 1.27%
240,040
+9,260
+4% +$483K
KTWO
29
DELISTED
K2M Group Holdings, Inc
KTWO
$12.7M 1.25%
+667,941
New +$13.2M
BIIB icon
30
Biogen
BIIB
$30B
$12.7M 1.25%
46,200
-6,100
-12% -$1.89M
GILD icon
31
Gilead Sciences
GILD
$166B
$12.6M 1.25%
167,200
-13,900
-8% -$1.1M
ESPR
32
DELISTED
Esperion Therapeutics
ESPR
$12.5M 1.24%
172,720
+164,920
+2,114% +$12.1M
AMGN icon
33
Amgen
AMGN
$198B
$11.7M 1.16%
68,700
-13,050
-16% -$2.4M
FIT
34
DELISTED
Fitbit, Inc. Class A common stock
FIT
$11.7M 1.16%
+2,295,400
New +$12.2M
BDX icon
35
Becton Dickinson
BDX
$43.1B
$10.8M 1.07%
51,250
-5,125
-9% -$1.12M
WMGI
36
DELISTED
Wright Medical Group Inc
WMGI
$10.7M 1.06%
541,801
– –
IART icon
37
Integra LifeSciences
IART
$1.49B
$10.6M 1.05%
191,000
+8,800
+5% +$461K
RMD icon
38
ResMed
RMD
$28.4B
$10.5M 1.04%
107,000
+60,000
+128% +$5.67M
CI icon
39
Cigna
CI
$75.2B
$9.67M 0.96%
57,650
– –
LH icon
40
Labcorp
LH
$23.2B
$9.66M 0.96%
69,526
+3,388
+5% +$498K
VTRS icon
41
Viatris
VTRS
$20.1B
$9.63M 0.95%
233,950
-2,350
-1% -$100K
REGN icon
42
Regeneron Pharmaceuticals
REGN
$70.7B
$9.43M 0.93%
27,380
-420
-2% -$146K
ZBH icon
43
Zimmer Biomet
ZBH
$17.4B
$9.05M 0.9%
85,490
– –
HCM icon
44
HUTCHMED
HCM
$1.91B
$8.94M 0.89%
302,420
+168,570
+126% +$5.99M
ALDR
45
DELISTED
Alder Biopharmaceuticals
ALDR
$8.9M 0.88%
700,464
+669,864
+2,189% +$9.69M
SHPG
46
DELISTED
Shire pic
SHPG
$8.73M 0.86%
58,435
+2,000
+4% +$275K
LIVN icon
47
LivaNova
LIVN
$4.42B
$8.38M 0.83%
94,724
-52,545
-36% -$4.48M
TSRO
48
DELISTED
TESARO, Inc.
TSRO
$8.27M 0.82%
144,802
+72,702
+101% +$4.68M
ABMD
49
DELISTED
Abiomed Inc
ABMD
$7.93M 0.79%
27,250
+250
+0.9% +$63.4K
INSM icon
50
Insmed
INSM
$23.4B
$7.53M 0.75%
+334,489
New +$8.8M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2018 Portfolio in Review

As of Q1 2018, Bellevue Group held 140 positions worth $1.01B, up 5.4% from $957M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group deployed $30.7M of net new capital in Q1 2018, opening 6 new positions and adding to 28 existing holdings. Its largest new stake was K2M Group Holdings, Inc: 667,941 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $11.4M trimmed.

  • Bellevue Group's largest Q1 2018 buy was K2M Group Holdings, Inc: 667,941 shares worth $12.7M.
  • Bellevue Group added most to Teladoc Health in Q1 2018, an estimated $17.7M increase.
  • Bellevue Group's biggest Q1 2018 reduction was Teva Pharmaceuticals, cutting an estimated $11.4M.
  • Bellevue Group fully exited Eli Lilly in Q1 2018, selling an estimated $20.4M.
  • Bellevue Group's ten largest holdings make up 33% of its $1.01B portfolio in Q1 2018.
  • Bellevue Group opened 6 new positions and closed 15 in Q1 2018.
  • Bellevue Group's portfolio value rose 5.4% quarter-over-quarter to $1.01B.

Based on Bellevue Group's 13F filing for Q1 2018, filed 9 May 2018.